Abstract:Abstract Background The therapeutic armamentarium for inflammatory bowel disease (IBD) is rapidly expanding as well as the number of elderly patients with IBD. Given the frailty of this subpopulation, it is of increasing importance to have data on the efficacy and safety of different therapies in this cohort. Aim: To assess the efficacy and severe adverse event (SAE) rate of different biologics in young (<60 years (yr)) versus elderly patients with IBD (≥60 yr) in a real-world tertiary cohort. Methods A retrospective monocentric study was performed at the Ghent University Hospital. Patients starting anti-TNF, ustekinumab (UST) or vedolizumab (VDZ) from 01/2018 to 06/2021 with follow-up until 12/2022 were included. Co-primary endpoints after induction and after 1 yr of therapy were: clinical response (CRp) and remission (CRm), biochemical response (BRp) and remission (BRm) and endoscopic response (ERp) and remission (ERm). The secondary endpoint was treatment survival. Severe adverse events (SAE) were defined as intestinal resection (IR), IBD-inflammation related hospitalization (IBD-hosp), IBD-treatment related hospitalization (e.g. infections) (treat-hosp), malignancy and death. Multivariate logistic regression (MLR) and Cox regression model (CRM) were applied to assess potential risk factors (RF). Results A total of 267 patients were included (33 patients ≥60 yr). Significantly different baseline characteristics are shown in Table 1A. After induction, no differences in CRp, CRm, BRp, ERp or ERm were found between both groups (Table 1B). Only BRm was numerically higher in younger patients, but not statistically significant after MLR (Table 1C). After one year of therapy, no difference was seen for CRp, CRm, BRp, BRm, ERp or ERm (Table 1B). There was no difference regarding treatment survival for both groups (aHR 0.701, [0.346-1.420], P=0.324) (figure 1), as well as for reason to stop biologic (P=0.336). Regarding SAEs, a higher rate was seen for elderly patients (26.9% vs. 45.5%, P=0.028), also after CRM (aHR 1.86, [1.01-3.44], P=0.047), adjusting for type of biologic, use of systemic corticosteroids or immunomodulators, previous IR, disease duration and number of previous biologics used. Regarding different subtypes of SAE, no difference for IR (P=0.503), IBD-hosp (P=0.714), specific IBD related SAE (P=0.480), malignancy (P=0.162) and death (P=1.000) were found. Treat-hosp was higher in elderly patients (5.1% vs. 24.2%, P=0.001), which was confirmed in the CRM (aHR 5.01, [1.92-13.04], P<0.001). Conclusion No difference was seen regarding efficacy of different biologics in younger versus elderly patients with IBD. SAE rate was higher in elderly patients.

What problem does this paper attempt to address?

This paper aims to evaluate the efficacy of different biologics and the incidence of serious adverse events (SAE) in young (<60 years old) and elderly (≥60 years old) patients with inflammatory bowel disease (IBD). Specifically, the research objective is to compare the clinical response, biochemical response, endoscopic response and treatment duration of patients in these two age groups after receiving anti - TNF drugs, Ustekinumab (UST) or Vedolizumab (VDZ) treatment, and analyze the occurrence of serious adverse events. ### Research Background With the continuous expansion of IBD treatment methods and the increase in the number of IBD patients in the elderly population, it is particularly important to understand the effectiveness and safety of these treatment methods in this vulnerable population. ### Research Methods - **Research Design**: Retrospective single - center study. - **Research Site**: Ghent University Hospital in Belgium. - **Research Subjects**: Patients who started using the above biologics from January 2018 to June 2021 and were followed up until December 2022. - **Primary Endpoints**: Clinical response (CRp), clinical remission (CRm), biochemical response (BRp), biochemical remission (BRm) and endoscopic response (ERp), endoscopic remission (ERm) during the induction period and 1 year after treatment. - **Secondary Endpoint**: Treatment duration. - **Statistical Methods**: Multivariate Logistic Regression (MLR) and Cox Regression Model (CRM) were used to evaluate potential risk factors. ### Main Results - **Baseline Characteristics**: There were significant differences between the two groups of patients at baseline (see Table 1A). - **Induction Period Effects**: - There were no significant differences in clinical response (CRp), clinical remission (CRm), biochemical response (BRp), endoscopic response (ERp) and endoscopic remission (ERm) between the two groups. - Biochemical remission (BRm) was numerically higher in young patients, but it was not statistically significant after MLR adjustment. - **One - Year - Later Effects**: - There were no significant differences in clinical response (CRp), clinical remission (CRm), biochemical response (BRp), biochemical remission (BRm), endoscopic response (ERp) and endoscopic remission (ERm) between the two groups. - **Treatment Duration**: - There was no significant difference in treatment duration between the two groups (adjusted hazard ratio \( \text{aHR} = 0.701 \), \([0.346 - 1.420]\), \( P = 0.324\)). - The reasons for stopping biologics were also not significantly different between the two groups (\( P = 0.336\)). - **Serious Adverse Events (SAE)**: - The incidence of SAE in elderly patients was significantly higher than that in young patients (26.9% vs. 45.5%, \( P = 0.028\)). - After CRM adjustment, the incidence of SAE in elderly patients was still significantly higher (adjusted hazard ratio \( \text{aHR} = 1.86\), \([1.01 - 3.44]\), \( P = 0.047\)), and the adjustment factors included the type of biologic, the use of systemic corticosteroids or immunomodulators, previous intestinal resection, disease duration and the number of previously used biologics. - Among the specific types of SAE, only treatment - related hospitalization (Treat - hosp) was significantly higher in elderly patients (5.1% vs. 24.2%, \( P < 0.001\)), which was confirmed by CRM (adjusted hazard ratio \( \text{aHR} = 5.01\), \([1.92 - 13.04]\), \( P < 0.001\)). ### Conclusions - There are no significant differences in the efficacy of different biologics in young and elderly IBD patients. - The incidence of serious adverse events in elderly patients is significantly higher, especially the situation of treatment - related hospitalization is more obvious.

P963 The comparative effectiveness and safety of different biologics in young (<60 years) versus elderly (≥60 years) patients with IBD: results from a real-world experience at a Belgian tertiary centre

A Real-Life Multicentric Cohort Study

A143 SAFETY OF BIOLOGICAL THERAPIES IN ELDERLY IBD: A SYSTEMATIC REVIEW

P834 Choosing wisely: Ustekinumab in Elderly Crohn’s Patients – A Comparative Study

RETROSPECTIVE, SINGLE-CENTER, REAL-WORLD ANALYSIS OF BIOLOGIC AND IMMUNOMODULATOR THERAPY DISCONTINUATION IN ELDERLY IBD PATIENTS

Comparative Safety and Effectiveness of Ustekinumab and Anti-TNF in Elderly Crohn's Disease Patients

P581 Age-related patterns in biological therapy use and surgery among patients with IBD: Insights from the Belgian PANTHER cohort

P539 Assessment of VEdolizumab aNd Ustekinumab in Elderly patients with Crohn’s disease (CD): the IG-IBD AVENUE study

SAFETY OF ANTI-TUMOR NECROSIS FACTOR AGENTS COMPARED TO USTEKINUMAB AND VEDOLIZUMAB IN ELDERLY PATIENTS WITH ULCERATIVE COLITIS

CHRONOLOGICAL AGE INFLUENCES TREATMENT DECISION IN INFLAMMATORY BOWEL DISEASE: AN IBD QORUS COLLABORATIVE STUDY

Comorbidity Influences the Comparative Safety of Biologic Therapy in Older Adults With Inflammatory Bowel Diseases

P705 Assessment of age on the efficacy and safety among patients in the etrasimod ELEVATE ulcerative colitis clinical programme

P627 Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naïve patients with Crohn’s disease by disease location: Results from the EVOLVE Expansion study

P694 Age is a strong of predictive risk factor for anti-TNF therapy related adverse events in IBD patients

Efficacy and safety of biotechnological drugs for the treatment of moderate-to-severe psoriasis in the elderly population: a single-center, Italian experience

Real world evidence of the association between medication and life expectancy in elderly inflammatory bowel disease: a population-based cohort study

A Focus on Disease Characteristics and Biological Therapy Patterns

Efficacy and Safety of Biological Therapies and JAK Inhibitors in Older Patients with Inflammatory Bowel Disease

Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review

Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice

P963 The comparative effectiveness and safety of different biologics in young (&lt;60 years) versus elderly (≥60 years) patients with IBD: results from a real-world experience at a Belgian tertiary centre